News Headline Summary

Sarepta Therapeutics (SRPT) files first patent application "Multiple Exon Skipping Compositions for DMD" in an nearly move to protect the Eteplirsen franchise

Reaction details:

- No immediate reaction seen in Co. shares, trades USD 36.55 last. (-2.97%)

Print 15:36, 25 Jul 2013 - US Equities - Source: Hammerstone